Overview
Background
Dr Mollee practices as a consultant haematologist in clinical and laboratory haematology at the Princess Alexandra Hospital and is Associate Professor with the University of Queensland Medical School.
Having trained in Brisbane and Toronto, Dr Mollee has developed an international reputation studying amyloidosis and the plasma cell dyscrasias. He holds appointments with the Medical Scientific Advisory Group of Myeloma Australia, Australian Amyloidosis Network, National Blood Cancer Taskforce and is a member of the AACB Monoclonal Gammopathy Working Group and the International Kidney & Monoclonal Gammopathy Research Group. He is a past Chairman of the Australasian Leukaemia and Lymphoma Group (ALLG) and current Chair of the Australian Amyloidosis Network. He heads the Myeloma Service as well as the Queensland Amyloidosis Centre which runs one of the few clinics in Australia dedicated exclusively to the care of patients with amyloidosis.
Availability
- Associate Professor Peter Mollee is:
- Available for supervision
Qualifications
- Masters (Coursework) of Medical Science, University of Newcastle
- Royal Australasian College of Physicians, Royal Australasian College of Physicians
- Royal College of Pathologists of Australasia, Royal College of Pathologists of Australasia
Research impacts
The research of the Queensland Amyloidosis Centre aims to improved the diagnosis, monitoring and therapy of all types of amyloidosis. The Centre, in collaboration with Pathology Queensland and the Translational Research Institute, developed laser capture macrodisscution and tandem mass spectrometry analysis to accurately diagnosis the type of amyloidosis that patients have and have introuduced this assay into the clinical laboratory. Research to improve the diagnosis and monitoring of this rare disease has also assessed immunoglobulin free light chain assays, bone scintigraphy and novel radionuclide PET tracers. The Queensland Amyloidosis Centre maintains an active clinical trial program in amyloidosis therapies including both investigator-initiated and commercial studies.
Works
Search Professor Peter Mollee’s works on UQ eSpace
2012
Conference Publication
Outcomes and prognostic factors for patients with Acute Myeloid Leukemia admitted to the intensive care unit
Jackson, Kathryn A., Mollee, Peter, Morris, Kirk, Jackson, Dwane L., Kruger, Peter, Klein, Kerenaftali and Kennedy, Glen A. (2012). Outcomes and prognostic factors for patients with Acute Myeloid Leukemia admitted to the intensive care unit. 54th Annual Meeting and Exposition of the American Society of Hematology (ASH), Atlanta, GA, United States, 8-11 December 2012. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood.V120.21.3613.3613
2012
Conference Publication
Intensive Chemotherapy for Acute Myeloid Leukemia in Elderly Patients
Jackson, Kathryn A., Kennedy, Glen A., Mollee, Peter and Morris, Kirk (2012). Intensive Chemotherapy for Acute Myeloid Leukemia in Elderly Patients. 54th Annual Meeting and Exposition of the American Society of Hematology (ASH), Atlanta, GA, United States, 8-11 December 2012. Washington, DC, United States: American Society of Hematology.
2011
Conference Publication
Tissue microarray in DLBCL patients receiving R-CHOP chemo-immunotherapy shows survival benefit for coexpression of LMO2/BCL6
Keane, Colm, Shen, Linda, Han, Erica, Nourse, Jamie P, Lea, Rod, Mollee, Peter, Gill, Devinder S and Gandhi, Maher K (2011). Tissue microarray in DLBCL patients receiving R-CHOP chemo-immunotherapy shows survival benefit for coexpression of LMO2/BCL6. 53rd ASH Annual Meeting, San Diego, 10-13 December 2011. American Society of Hematology. doi: 10.1182/blood.v118.21.1585.1585
2011
Conference Publication
A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis
Mollee, Peter, Tiley, Campbell, Cunningham, Ilona, Moore, John, Prince, Miles, Cannell, Paul, Gibbons, Steve, Tate, Jill, Paul, Sanjoy and Gill, Devinder S (2011). A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis. 53rd ASH Annual Meeting, San Diego, 10-13 December 2011. American Society of Hematology. doi: 10.1182/blood.v118.21.3973.3973
2011
Conference Publication
ZAP-70 expression measured by quantitative PCR (QPCR) as a prognostic marker in chronic lymphocytic leukaemia (CLL)
Mollee, Peter, Banh, Raymond H., Cheung, Catherine, Saal, Russell, Chambers, Lynne, Pelly, Tennille and Gill, Devinder S (2011). ZAP-70 expression measured by quantitative PCR (QPCR) as a prognostic marker in chronic lymphocytic leukaemia (CLL). 53rd ASH Annual Meeting, San Diego, 10-13 December 2011. American Society of Hematology. doi: 10.1182/blood.v118.21.4602.4602
2011
Journal Article
Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes
Nguyen-Van, Do, Keane, Colm, Han, Erica, Jones, Kimberley, Nourse, Jamie P., Vari, Frank, Ross, Nathan, Crooks, Pauline, Ramuz, Olivier, Green, Michael, Griffith, Lyn, Trappe, Ralf, Grigg, Andrew, Mollee, Peter and Gandhi, Maher K. (2011). Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes. American Journal of Blood Research, 1 (2), 146-159.
2011
Journal Article
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial
Coiffier, Bertrand, Osmanov, Evgenii A., Hong, Xiaonan, Scheliga, Adriana, Mayer, Jiri, Offner, Fritz, Rule, Simon, Teixeira, Adriana, Walewski, Jan, de Vos, Sven, Crump, Michael, Shpilberg, Ofer, Esseltine, Dixie-Lee, Zhu, Eugene, Enny, Christopher, Theocharous, Panteli, van de Velde, Helgi, Elsayed, Yusri A., Zinzani, Pier Luigi, LYM-3001 study investigators and Mollee, Peter (2011). Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. The Lancet Oncology, 12 (8), 773-84. doi: 10.1016/S1470-2045(11)70150-4
2011
Journal Article
Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: A prospective cohort study
Mollee, P., Jones, M., Stackelroth, J., van Kuilenburg, R., Joubert, W., Faoagali, J., Looke, D., Harper, J. and Clements, A. (2011). Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: A prospective cohort study. Journal of Hospital Infection, 78 (1), 26-30. doi: 10.1016/j.jhin.2011.01.018
2011
Journal Article
Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia
Weston, H., Cowell, V., Grimmett, K., Saal, R., Jones, M., Mills, T., Gill, D., Marlton, P., Bird, R. and Mollee, P. (2011). Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia. Internal Medicine Journal, 41 (5), 408-415. doi: 10.1111/j.1445-5994.2010.02334.x
2011
Conference Publication
A Phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis
Mollee, Peter, Tiley, Campbell, Cunningham, Ilona, Moore, John, Prince, Miles, Cannell, Paul, Gibbons, Steve, Tate, Jill, Paul, Sanjoy and Gill, Devinder S. (2011). A Phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis. 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH), San Diego, CA, United States, Dec 10-13, 2011. Washington, DC, United States: American Society of Hematology.
2011
Conference Publication
Analytical aspects of standardised protein electrophoresis and immunofixation reporting
Tate, Jill, for the Working Party on Standardised Reporting of Protein Electrophoresis, Mollee, Peter, Caldwell, Grahame, Daly, James, Gillis, David, Jenkins, Margaret, Jovanovich, Sue, Martin, Helen, Steele, Richard and Wienholt, Louise (2011). Analytical aspects of standardised protein electrophoresis and immunofixation reporting. 35th Annual Scientific Meeting of the Australasian Division of the International Academy of Pathology, Sydney, NSW Australia, 4-6 June 2010. Oxford, United Kingdom: Elsevier. doi: 10.1016/s0031-3025(16)33167-1
2011
Journal Article
Treatment of acute promyelocytic leukaemia in the Jehovah's Witness population
Keane, Colm, Mollee, Peter, Marlton, Paula and Gill, Devinder (2011). Treatment of acute promyelocytic leukaemia in the Jehovah's Witness population. Annals of Hematology, 90 (3), 359-360. doi: 10.1007/s00277-010-1023-0
2011
Conference Publication
Recommendations for Standardised Reporting of Protein Electrophoresis in Australia and New Zealand
Tate, J., Mollee, P., Caldwell, G., Daly, J., Gillis, D., Jenkins, M., Jovanovich, S., Martin, H., Steele, R., Wienholt, L. and AACB Working Party Standardised Reporting of Protein Electrophoresis (2011). Recommendations for Standardised Reporting of Protein Electrophoresis in Australia and New Zealand. EuroMedLab Berlin 2011, Berlin, Germany, 15-19 May 2011. Berlin, Germany: Walter De Gruyter. doi: 10.1515/CCLM.2011.527
2011
Journal Article
Outcome of treatment of adult acute lymphoblastic leukemia with hyperfractionated cyclophosphamide, doxorubicin, vincristine, dexamethasone/methotrexate, cytarabine: Results from an Australian population
Morris, Kirk, Weston, Helen, Mollee, Peter, Marlton, Paula, Gill, Devinder and Kennedy, Glen (2011). Outcome of treatment of adult acute lymphoblastic leukemia with hyperfractionated cyclophosphamide, doxorubicin, vincristine, dexamethasone/methotrexate, cytarabine: Results from an Australian population. Leukemia and Lymphoma, 52 (1), 85-91. doi: 10.3109/10428194.2010.532889
2011
Conference Publication
Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6
Keane, C, Shen, L, Han, E, Nourse, JP, Lea, R, Mollee, P, Gill, DS and Gandhi, MK (2011). Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), San Diego Ca, Dec 10-13, 2011. WASHINGTON: AMER SOC HEMATOLOGY.
2011
Journal Article
Proteomics in molecular diagnosis: typing of amyloidosis
Loo, Dorothy, Mollee, Peter N., Renaut, Patricia and Hill, Michelle M. (2011). Proteomics in molecular diagnosis: typing of amyloidosis. Journal of Biomedicine and Biotechnology, 2011 (1) 754109, 754109.1-754109.9. doi: 10.1155/2011/754109
2011
Conference Publication
Rapid diagnosis of heparin-induced thrombocytopenia (HIT) by whole blood impedance aggregometry: results of the Australian multi centre study
Morel-Kopp, MC, Tan, CW, Brighton, T, McRae, S, Tran, H, Mollee, P, Kershaw, G, Joseph, J, Coyle, L and Ward, C (2011). Rapid diagnosis of heparin-induced thrombocytopenia (HIT) by whole blood impedance aggregometry: results of the Australian multi centre study. Unknown, unknown, unknown. HOBOKEN: WILEY-BLACKWELL.
2010
Conference Publication
WT1 Expression as a marker of minimal residual disease, predicts outcome in acute myeloid leukaemia when measured at post-consolidation
Gray, James X., McMillen, Lyle, Saal, Russell, Lane, Steven, Bird, Robert, Gill, Devinder, Mollee, Peter and Marlton, Paula (2010). WT1 Expression as a marker of minimal residual disease, predicts outcome in acute myeloid leukaemia when measured at post-consolidation. Royal College of Pathologists of Australasia Pathology Update, Melbourne, VIC Australia, 26-28 February 2010. Oxford, United Kingdom: Elsevier. doi: 10.1097/01268031-201042001-00118
2010
Conference Publication
Survival and prognostic factors amongst Australian patients with AL amyloidosis
Mollee, P, Tate, J, Morris, K, Wellwood, J, Browne, M, Marlton, P, Bird, R, Mills, AK, Wood, P, Mapp, S and Gill, D (2010). Survival and prognostic factors amongst Australian patients with AL amyloidosis. 12th International Symposium on Amyloidosis from Molecular Mechanisms Toward the Cure of Systemic Amyloidoses, Rome Italy, Apr 18-21, 2010. LONDON: INFORMA HEALTHCARE.
2010
Conference Publication
Assessment of a monoclonal antibody-based free light chain enzyme-linked immunosorbent assay (ELISA) and the polyclonal antibody-based Freelite assay in AL amyloidosis
Mollee, P., Tate, J., Weiss, D. and Solomon, A. (2010). Assessment of a monoclonal antibody-based free light chain enzyme-linked immunosorbent assay (ELISA) and the polyclonal antibody-based Freelite assay in AL amyloidosis. 12th International Symposium on Amyloidosis from Molecular Mechanisms Toward the Cure of Systemic Amyloidoses, Rome, Italy, 18-21, April 2010. London, United Kingdom: Informa Healthcare.
Funding
Current funding
Past funding
Supervision
Availability
- Associate Professor Peter Mollee is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Master Philosophy
Novel Radionuclide Tracers for Imaging in Amyloidosis
Principal Advisor
Other advisors: Associate Professor Colm Keane
-
Doctor Philosophy
Addressing frailty in older people with haematological malignancies
Associate Advisor
Other advisors: Associate Professor Emily Gordon, Dr Natasha Reid, Professor Ruth Hubbard
Media
Enquiries
For media enquiries about Associate Professor Peter Mollee's areas of expertise, story ideas and help finding experts, contact our Media team: